• +353-1-416-8900(GMT OFFICE HOURS)
  • 1-800-526-8630(US/CAN TOLL FREE)
  • 1-917-300-0470(EST OFFICE HOURS)
The Avicena Group, Inc. - Product Pipeline Review - Q1 2011 Product Image

The Avicena Group, Inc. - Product Pipeline Review - Q1 2011

  • ID: 1841921
  • June 2011
  • 21 pages
  • Global Markets Direct

The Avicena Group, Inc. – Product Pipeline Review – Q1 2011

Summary

Global Market Direct’s pharmaceuticals report, “The Avicena Group, Inc. - Product Pipeline Review - Q1 2011” provides data on the The Avicena Group, Inc.’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

This report is built using data and information sourced from Global Markets Direct’s proprietary databases, The Avicena Group, Inc.’s corporate website, SEC filings, investor presentations and featured press releases, both from The Avicena Group, Inc. and industry-specific third party sources, put together by Global Markets Direct’s team.

Scope

- The Avicena Group, Inc. - Brief The Avicena Group, Inc. overview including business description, key information and facts, and its locations and subsidiaries.
- Review of current pipeline of The Avicena Group, Inc. human therapeutic division.
- Overview of pipeline therapeutics across various therapy areas.
- Coverage of current pipeline molecules READ MORE >



List of Tables
List of Figures
The Avicena Group, Inc. Snapshot
The Avicena Group, Inc. Overview
Key Information
Key Facts
The Avicena Group, Inc. – Research and Development Overview
Key Therapeutic Areas
The Avicena Group, Inc. – Pipeline Review
Pipeline Products by Stage of Development
Pipeline Products – Monotherapy
The Avicena Group, Inc. – Pipeline Products Glance
The Avicena Group, Inc. – Late Stage Pipeline
Phase III Products/Combination Treatment Modalities
The Avicena Group, Inc. Clinical Stage Pipeline Products
Phase II Products/Combination Treatment Modalities
Phase I Products/Combination Treatment Modalities
The Avicena Group, Inc. – Drug Profiles
ALS-02
Product Description
Mechanism of Action
R&D Progress
HD-02
Product Description
Mechanism of Action
R&D Progress
DMD-02
Product Description
Mechanism of Action
R&D Progress
The Avicena Group, Inc. – Pipeline Analysis
The Avicena Group, Inc. – Pipeline Products by Therapeutic Class
The Avicena Group, Inc. - Pipeline Products By Target
The Avicena Group, Inc. – Pipeline Products by Route of Administration
The Avicena Group, Inc. - Dormant Projects
The Avicena Group, Inc. – Locations And Subsidiaries
Head Office
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
The Avicena Group, Inc. – Pipeline by Therapy Area and Indication, 2011
The Avicena Group, Inc. – Pipeline by Stage of Development, 2011
The Avicena Group, Inc. – Monotherapy Products in Pipeline, 2011
The Avicena Group, Inc. – Phase III, 2011
The Avicena Group, Inc. - Phase II, 2011
The Avicena Group, Inc. - Phase I, 2011
The Avicena Group, Inc. - Pipeline By Therapeutic Class, 2011
The Avicena Group, Inc. - Pipeline By Target, 2011
The Avicena Group, Inc. – Pipeline By Route of Administration, 2011
The Avicena Group, Inc. - Dormant Developmental Projects, 2010

List of Figures
The Avicena Group, Inc. – Pipeline by Therapy Area and Indication, 2011
The Avicena Group, Inc. – Pipeline by Stage of Development, 2011
The Avicena Group, Inc. – Monotherapy Products in Pipeline, 2011
The Avicena Group, Inc. – Pipeline By Therapeutic Class, 2011

Note: Product cover images may vary from those shown

RELATED PRODUCTS

Our Clients

Our clients' logos